2-(2,2-dimethylpropylamino)pyridine | 111098-38-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(2,2-dimethylpropylamino)pyridine
• 英文别名: N-(2,2-dimethylpropyl)pyridin-2-amine
• CAS: 111098-38-5
• 化学式: C₁₀H₁₆N₂
• 分子量: 164.25
• InChiKey: LDKRDTGJDTXAGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-((3-(1-cyclopropyl-3-ethoxy-3-oxopropyl)phenoxy)methyl)-piperidin-1-yl)-4-methoxybenzoic acid 、 2-(2,2-dimethylpropylamino)pyridine 在 1-氯-N,N,2-三甲基丙烯胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 2.5h， 生成 3-cyclopropyl-3-(3-((1-(2-((2,2-dimethylpropyl)(pyridin-2-yl)carbamoyl)-5-methoxyphenyl)piperidin-4-yl)methoxy)phenyl)propanoic acid
  参考文献：
  名称：

  Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety

  摘要：

  GPR40/FFAR1 is a G-protein-coupled receptor expressed in pancreatic beta-cells and enteroendocrine cells. GPR40 activation stimulates secretions of insulin and incretin, both of which are the pivotal regulators of glycemic control. Therefore, a GPR40 agonist is an attractive target for the treatment of type 2 diabetes mellitus. Using the reported biaryl derivative 1, we shifted the hydrophobic moiety to the terminal aryl ring and replaced the central aryl ring with piperidine, generating 2-(4,4-dimethylpentyl)phenyl piperidine 4a, which had improved potency for GPR40 and high lipophilicity. We replaced the hydrophobic moiety with N-alkyl-N-aryl benzamides to lower the lipophilicity and restrict the N-alkyl moieties to the presumed lipophilic pocket using the intramolecular pi-pi stacking of cis-preferential N-alkyl-N-aryl benzamide. Among these, orally available (3S)-3-cyclopropyl-3-(2-((1-(2-((2,2-dimethylpropyl)(6-methylpyridin-2-yl)carbamoyl)-5-methoxyphenyl)piperidin-4-yl)methoxy)pyridin-4-yl)propanoic acid (SCO-267) effectively stimulated insulin secretion and GLP-1 release and ameliorated glucose tolerance in diabetic rats via GPR40 full agonism.

  DOI：

  10.1021/acs.jmedchem.0c00843
• 作为产物：
  描述：

  (1-Benzotriazol-1-yl-2,2-dimethyl-propyl)-pyridin-2-yl-amine 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 以96%的产率得到2-(2,2-dimethylpropylamino)pyridine
  参考文献：
  名称：

  Katritzky, Alan R.; Rachwal, Stanislaw; Rachwal, Bogumila, Journal of the Chemical Society. Perkin transactions I, 1987, p. 805 - 810

  摘要：

  DOI：

文献信息

• IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS
  申请人：Venkataramani Chandrasekar

  公开号：US20100009990A1

  公开（公告）日：2010-01-14

  A compound of general Formula (I) having histone deacetylase (HDAC) and/or Cyclin-dependent kinase (CDK) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.

  具有组蛋白去乙酰化酶（HDAC）和/或 Cyclin 依赖性激酶（CDK）抑制活性的一般式（I）化合物，包括该化合物的药物组合物，以及使用该化合物治疗疾病的有效方法。
• AROMATIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160115128A1

  公开（公告）日：2016-04-28

  Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

  提供一种具有GPR40激动剂活性和GLP-1分泌素作用的新型芳香环化合物。具有下式表示的化合物： 其中每个符号如描述中所述，或其盐具有GPR40激动剂活性和GLP-1分泌素作用，对于预防或治疗癌症、肥胖症、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌少症等疾病具有用处，并且具有卓越的疗效。
• BISPHOSPHONATE COMPOUNDS
  申请人：Ebetino Frank Hallock

  公开号：US20110098251A1

  公开（公告）日：2011-04-28

  Novel bisphosphonate cyclic acetal compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating bone metabolism disorders, such as abnormal calcium and phosphate metabolism.

  揭示了一种新型的双膦酸环缩醛化合物，以及制备这些化合物的方法，包括这些化合物的药物组合物，以及在治疗骨代谢紊乱的方法中给予这些化合物的方法，例如异常的钙和磷代谢。
• PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
  申请人：Banka Anna

  公开号：US20110053959A1

  公开（公告）日：2011-03-03

  The present invention provides compounds of Formula (I) including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer.

  本发明提供了公式（I）的化合物，包括互变异构体、分离的对映体、分离的二对映异构体、溶剂化物、代谢物、盐和其药学上可接受的前药。还提供了使用本发明化合物作为Akt蛋白激酶抑制剂和用于治疗Akt介导的疾病（例如，癌症等增殖性疾病）的方法。
• Substituted quinazoline compounds and methods of use thereof
  申请人：Araxes Pharma LLC

  公开号：US10829458B2

  公开（公告）日：2020-11-10

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have one of the following structures (I), (II) or (III): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5a, R5b, R6, A, B, G1, G2, L1, L2, m1, m2, n, x, y, X and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  本研究提供了具有抑制 G12C 突变 KRAS 蛋白活性的化合物。这些化合物具有以下结构之一 (I)、(II) 或 (III)： 或其药学上可接受的盐、立体异构体或原药，其中 R1、R2a、R2b、R2c、R3a、R3b、R4a、R4b、R5a、R5b、R6、A、B、G1、G2、L1、L2、m1、m2、n、x、y、X 和 E 如本文所定义。还提供了与制备和使用此类化合物相关的方法、包含此类化合物的药物组合物以及调节G12C突变型KRAS蛋白活性以治疗疾病（如癌症）的方法。